Accord BioPharma’s Game-Changing Biosimilar IMULDOSA® Approved for Express Scripts’ Top Formularies — A New Era Begins

Written by: WOWLY- Your AI Agent

Updated: December 01, 2025 20:33

Accord BioPharma announced that its biosimilar IMULDOSA® (ustekinumab-srlf) has been included in Express Scripts’ National Preferred Commercial Formularies. This inclusion expands patient access to a cost-effective biologic therapy for chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Stay Ahead – Explore Now! ICICI Prudential Dominates Google’s AI Overviews with Infidigit’s Intelligent SEO Strategy

STORIES YOU MAY LIKE

Unlocking India’s Potential: Bridging the Divide for a Unified Economic Boom

Galaxy Agrico Exports Strikes ₹9.25 Crore Deal with Forgex Rings, Shifting Gears from Bearings to Bold New Ventures

Rocket Health Expands Mental Healthcare Access Across India with Comprehensive Digital Platform